Wilkinson J, Foo K, Sekhri N, Cooper J, Suliman A, Ranjadayalan K, Timmis A D
Department of Cardiology Newham HealthCare NHS Trust, London, UK.
Heart. 2002 Dec;88(6):583-6. doi: 10.1136/heart.88.6.583.
Shortening prehospital delay has been identified as an important means of improving responses to reperfusion treatment. If this increases the risk profile of the population delivered to hospital, it may paradoxically cause a deterioration in hospital mortality.
To examine the interaction between arrival time (time from onset of chest pain to arrival at hospital) and thrombolytic treatment in determining the early outcome of acute myocardial infarction.
Prospective cohort study of 1723 patients with acute myocardial infarction who were potentially eligible for thrombolytic treatment (ST elevation on ECG; arrival time < or = 12 hours).
All patients were eligible for thrombolysis but only 1098 (80%) received it. Patients who did not receive thrombolytic treatment were older (66 (58-73) v 61 (53-70) years, p < 0.001), more commonly female (32.1% v 24.8%, p < 0.01), and had higher frequencies of previous infarction (28.6% v 15.6%, p < 0.001) and left ventricular failure (37.5% v 26.9%, p < 0.01) than patients who received thrombolytic treatment. For the group as a whole, 30 day mortality was 11.7% and was unaffected by arrival time, but in patients who did not receive thrombolysis an arrival time of < or = 6 hours was associated with significantly higher 30 day mortality than an arrival time of 6-12 hours (24.3% v 2.6%, p = 0.002). Conversely, in patients who did receive thrombolysis an arrival time of < or = 6 hours was associated with a lower 30 day mortality than an arrival time of 6-12 hours (8.5% v 14.5%, p < 0.02).
Shortening prehospital delay in acute myocardial infarction will tend to increase the risk profile of patients presenting to emergency departments. The data presented here indicate that this may increase hospital mortality if underutilisation of thrombolytic treatment among high risk groups is not diminished.
缩短院前延误时间已被视为改善再灌注治疗反应的重要手段。如果这增加了送至医院的人群的风险状况,可能反而会导致医院死亡率恶化。
研究到达时间(从胸痛发作到抵达医院的时间)与溶栓治疗之间的相互作用对急性心肌梗死早期结局的影响。
对1723例可能适合溶栓治疗(心电图ST段抬高;到达时间≤12小时)的急性心肌梗死患者进行前瞻性队列研究。
所有患者均适合溶栓治疗,但只有1098例(80%)接受了治疗。未接受溶栓治疗的患者年龄更大(66(58 - 73)岁对61(53 - 70)岁,p<0.001),女性更常见(32.1%对24.8%,p<0.01),既往梗死(28.6%对15.6%,p<0.001)和左心室衰竭(37.5%对26.9%,p<0.01)的发生率高于接受溶栓治疗的患者。总体而言,30天死亡率为11.7%,不受到达时间影响,但在未接受溶栓治疗的患者中,到达时间≤6小时的30天死亡率显著高于到达时间为6 - 12小时的患者(24.3%对2.6%,p = 0.002)。相反,在接受溶栓治疗的患者中,到达时间≤6小时的30天死亡率低于到达时间为6 - 12小时的患者(8.5%对14.5%,p<0.02)。
缩短急性心肌梗死的院前延误时间往往会增加急诊科就诊患者的风险状况。此处提供的数据表明,如果高危组中溶栓治疗的未充分利用情况没有改善,这可能会增加医院死亡率。